FindTrial
Sign In

Exploratory analysis of effect of intravitreal ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy.

Exploratory analysis of effect of intravitreal ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-16009520
Enrollment
Unknown
Registered
2016-10-20
Start date
2016-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

proliferative diabetic retinopathy

Interventions

Case series:intravitreal Ranibizumab

Sponsors

Department of Ophthalmology of The Second Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients were included if they had vitreous haemorrhage (VH) and tractional retinal detachment (TRD) consequent to active proliferative diabetic retinopathy; 2. Informed and voluntary to participate in the clinical trial.

Exclusion criteria

Exclusion criteria: 1. With other ocular diseases; 2. Subjects want to withdraw from the trial anytime.

Design outcomes

Primary

MeasureTime frame
visual acurity;Tractional retinal detachment;—

Countries

China

Contacts

Public ContactJun Zeng

Department of Ophthalmology of The Second Xiangya Hospital, Central South University

zengjun607@163.com+86 13017193119

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026